Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.52
ABBV's Cash to Debt is ranked higher than
59% of the 906 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.43 vs. ABBV: 0.52 )
ABBV' s 10-Year Cash to Debt Range
Min: 0.5   Max: No Debt
Current: 0.52

Equity to Asset 0.16
ABBV's Equity to Asset is ranked lower than
52% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. ABBV: 0.16 )
ABBV' s 10-Year Equity to Asset Range
Min: -0.01   Max: 0.69
Current: 0.16

-0.01
0.69
Interest Coverage 18.94
ABBV's Interest Coverage is ranked higher than
62% of the 546 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.95 vs. ABBV: 18.94 )
ABBV' s 10-Year Interest Coverage Range
Min: 18.94   Max: 9999.99
Current: 18.94

18.94
9999.99
F-Score: 6
Z-Score: 4.34
M-Score: -2.75
WACC vs ROIC
13.83%
41.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 27.33
ABBV's Operating margin (%) is ranked higher than
95% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.41 vs. ABBV: 27.33 )
ABBV' s 10-Year Operating margin (%) Range
Min: 20.75   Max: 34.7
Current: 27.33

20.75
34.7
Net-margin (%) 18.92
ABBV's Net-margin (%) is ranked higher than
92% of the 855 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.06 vs. ABBV: 18.92 )
ABBV' s 10-Year Net-margin (%) Range
Min: 19.68   Max: 32.62
Current: 18.92

19.68
32.62
ROE (%) 82.02
ABBV's ROE (%) is ranked higher than
100% of the 876 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.84 vs. ABBV: 82.02 )
ABBV' s 10-Year ROE (%) Range
Min: 57.54   Max: 199.32
Current: 82.02

57.54
199.32
ROA (%) 12.92
ABBV's ROA (%) is ranked higher than
94% of the 909 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.17 vs. ABBV: 12.92 )
ABBV' s 10-Year ROA (%) Range
Min: 14.69   Max: 35.17
Current: 12.92

14.69
35.17
ROC (Joel Greenblatt) (%) 129.15
ABBV's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.06 vs. ABBV: 129.15 )
ABBV' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 147.23   Max: 244.26
Current: 129.15

147.23
244.26
» ABBV's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ABBV Guru Trades in Q1 2014

Joel Greenblatt 229,149 sh (+120.38%)
Jim Simons 2,796,900 sh (+54.56%)
PRIMECAP Management 6,335,722 sh (+8.29%)
Mario Gabelli 10,462 sh (+3.79%)
Murray Stahl 35,882 sh (+1.69%)
Pioneer Investments 2,045,676 sh (+0.42%)
Dodge & Cox 36,701 sh (+0.14%)
Westport Asset Management 180,000 sh (unchged)
John Hussman 303,250 sh (unchged)
Jeff Auxier 78,440 sh (unchged)
Robert Bruce 231,300 sh (unchged)
Tom Russo 86,777 sh (unchged)
Paul Tudor Jones Sold Out
David Dreman Sold Out
Vanguard Health Care Fund Sold Out
Manning & Napier Advisors, Inc 146,077 sh (-2%)
Bill Frels 269,936 sh (-3.49%)
Ken Fisher 627,139 sh (-45.03%)
Steven Cohen 519,107 sh (-52.3%)
George Soros 350,000 sh (-69.5%)
Jeremy Grantham 66,200 sh (-76.7%)
» More
Q2 2014

ABBV Guru Trades in Q2 2014

Paul Tudor Jones 257,344 sh (New)
Louis Moore Bacon 185,000 sh (New)
Jana Partners 75,000 sh (New)
Lee Ainslie 3,235,133 sh (New)
NWQ Managers 83,878 sh (New)
Ken Fisher 1,104,609 sh (+76.13%)
Manning & Napier Advisors, Inc 192,029 sh (+31.46%)
Westport Asset Management 180,000 sh (unchged)
Robert Bruce 231,300 sh (unchged)
Tom Russo 86,777 sh (unchged)
Jeremy Grantham Sold Out
Dodge & Cox 36,649 sh (-0.14%)
PRIMECAP Management 6,304,122 sh (-0.5%)
Mario Gabelli 10,382 sh (-0.76%)
John Hussman 300,000 sh (-1.07%)
Pioneer Investments 2,014,581 sh (-1.52%)
Murray Stahl 35,273 sh (-1.7%)
Bill Frels 264,316 sh (-2.08%)
Jeff Auxier 73,421 sh (-6.4%)
Jim Simons 2,233,600 sh (-20.14%)
George Soros 150,000 sh (-57.14%)
Joel Greenblatt 88,923 sh (-61.19%)
» More
Q3 2014

ABBV Guru Trades in Q3 2014

Steve Mandel 5,247,201 sh (New)
Steven Cohen 184,300 sh (New)
Andreas Halvorsen 10,769,105 sh (New)
John Paulson 13,000,000 sh (New)
George Soros 1,537,146 sh (+924.76%)
Lee Ainslie 4,723,578 sh (+46.01%)
Jana Partners 100,000 sh (+33.33%)
Pioneer Investments 2,601,836 sh (+29.15%)
Dodge & Cox 38,849 sh (+6%)
NWQ Managers 85,948 sh (+2.47%)
PRIMECAP Management 6,454,836 sh (+2.39%)
Paul Tudor Jones 261,700 sh (+1.69%)
Tom Russo 86,777 sh (unchged)
Westport Asset Management 180,000 sh (unchged)
Mario Gabelli 10,382 sh (unchged)
Robert Bruce 231,300 sh (unchged)
Murray Stahl 35,265 sh (-0.02%)
Bill Frels 263,837 sh (-0.18%)
Manning & Napier Advisors, Inc 186,088 sh (-3.09%)
Ken Fisher 999,768 sh (-9.49%)
Louis Moore Bacon 80,000 sh (-56.76%)
Jeff Auxier 27,371 sh (-62.72%)
John Hussman 100,000 sh (-66.67%)
Jim Simons 722,355 sh (-67.66%)
Joel Greenblatt 9,460 sh (-89.36%)
» More
Q4 2014

ABBV Guru Trades in Q4 2014

Ken Fisher 1,001,105 sh (+0.13%)
» More
» Details

Insider Trades

Latest Guru Trades with ABBV

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
John Paulson 2014-09-30 New Buy3.1%$52.05 - $59.62 $ 63.1214%13000000
Andreas Halvorsen 2014-09-30 New Buy2.5%$52.05 - $59.62 $ 63.1214%10769105
Lee Ainslie 2014-09-30 Add 46.01%1.26%$52.05 - $59.62 $ 63.1214%4723578
Steve Mandel 2014-09-30 New Buy1.2%$52.05 - $59.62 $ 63.1214%5247201
John Hussman 2014-09-30 Reduce -66.67%0.87%$52.05 - $59.62 $ 63.1214%100000
George Soros 2014-09-30 Add 924.76%0.6%$52.05 - $59.62 $ 63.1214%1537146
Joel Greenblatt 2014-09-30 Reduce -89.36%0.06%$52.05 - $59.62 $ 63.1214%9460
Lee Ainslie 2014-06-30 New Buy2.6%$46.46 - $56.79 $ 63.1220%3235133
Joel Greenblatt 2014-06-30 Reduce -61.19%0.11%$46.46 - $56.79 $ 63.1220%88923
George Soros 2014-06-30 Reduce -57.14%0.1%$46.46 - $56.79 $ 63.1220%150000
Ken Fisher 2014-06-30 Add 76.13%0.06%$46.46 - $56.79 $ 63.1220%1104609
NWQ Managers 2014-06-30 New Buy0.05%$46.46 - $56.79 $ 63.1220%83878
George Soros 2014-03-31 Reduce -69.5%0.35%$46.83 - $53.68 $ 63.1225%350000
Vanguard Health Care Fund 2014-03-31 Sold Out 0.28%$46.83 - $53.68 $ 63.1225%0
Joel Greenblatt 2014-03-31 Add 120.38%0.1%$46.83 - $53.68 $ 63.1225%229149
Ken Fisher 2014-03-31 Reduce -45.03%0.06%$46.83 - $53.68 $ 63.1225%627139
David Dreman 2014-03-31 Sold Out 0.02%$46.83 - $53.68 $ 63.1225%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Guru Investment Theses on AbbVie Inc

Lountzis Asset Management Comments on Abbvie - Mar 21, 2014

ABBVIE (ABBV), spun off from Abbott, represents their research-based proprietary pharmaceutical business and is led by its highly profitable Humira franchise. Humira makes up approximately 50% of revenues and over 70% of profits. While AbbVie is focused on growing its pipeline, the reality is Humira, the leading rheumatoid arthritis drug, will continue to drive the revenue and profit growth for AbbVie until some of the experimental drugs they are working on such as its Hepatitis C virus drug gains FDA approval and enters the market. As a result, we are reviewing our holding of AbbVie at this time given its enormous concentration on one drug. While it continues to lead in many areas and it continues to grow around the world, it remains a concern for us. AbbVie’s revenues in 2013 exceeded $18.8 billion with operating earnings of $5.7 billion.



From Lountzis Asset Management 2013 Annual Letter



Check out latest stock trades

Top Ranked Articles about AbbVie Inc

John Paulson's Top 5 New Holdings For Q3
John Paulson (Trades, Portfolio)’s hedge fund Paulson & Co. was founded in 1994 and has $22.8 billion in assets under management as of Jul 2014. The fund focuses primarily on event-driven arbitrage situations. Paulson’s top strategies, the Advantage and Advantage Plus funds, lost 4.8 percent and 3.9 percent this year through August, the New York Times reported. Read more...
The 5 Most-Owned Spin-Offs of Investment Gurus
Numerous financiers, including Joel Greenblatt (Trades, Portfolio), have posited that investors can beat the market by investing in spin-offs – small portions of larger companies separated to stand as their own, independent company. But is this true? This is a question that GuruFocus writer Vera Yuan pondered in her article, “Can Spin-Offs Beat the Market?” Her research concluded that 52 weeks after being spun off, all spun-off companies since 2009 collectively outperformed the market by 84.28%. For this reason, GuruFocus introduced the “Spin-Off List” screener, which tracks all companies spun off since 2013. Read more...
Lountzis Asset Management Comments on Abbvie
ABBVIE (ABBV), spun off from Abbott, represents their research-based proprietary pharmaceutical business and is led by its highly profitable Humira franchise. Humira makes up approximately 50% of revenues and over 70% of profits. While AbbVie is focused on growing its pipeline, the reality is Humira, the leading rheumatoid arthritis drug, will continue to drive the revenue and profit growth for AbbVie until some of the experimental drugs they are working on such as its Hepatitis C virus drug gains FDA approval and enters the market. As a result, we are reviewing our holding of AbbVie at this time given its enormous concentration on one drug. While it continues to lead in many areas and it continues to grow around the world, it remains a concern for us. AbbVie’s revenues in 2013 exceeded $18.8 billion with operating earnings of $5.7 billion. Read more...

Ratios

vs
industry
vs
history
P/E(ttm) 27.30
ABBV's P/E(ttm) is ranked higher than
84% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.40 vs. ABBV: 27.30 )
ABBV' s 10-Year P/E(ttm) Range
Min: 9.86   Max: 30.3
Current: 27.3

9.86
30.3
Forward P/E 12.38
ABBV's Forward P/E is ranked higher than
94% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 56.18 vs. ABBV: 12.38 )
N/A
PE(NRI) 26.90
ABBV's PE(NRI) is ranked higher than
84% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 49.90 vs. ABBV: 26.90 )
ABBV' s 10-Year PE(NRI) Range
Min: 9.85   Max: 30.31
Current: 26.9

9.85
30.31
P/B 21.50
ABBV's P/B is ranked higher than
51% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.71 vs. ABBV: 21.50 )
ABBV' s 10-Year P/B Range
Min: 15.75   Max: 25.22
Current: 21.5

15.75
25.22
P/S 5.10
ABBV's P/S is ranked higher than
68% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.02 vs. ABBV: 5.10 )
ABBV' s 10-Year P/S Range
Min: 2.83   Max: 5.72
Current: 5.1

2.83
5.72
PFCF 21.20
ABBV's PFCF is ranked higher than
93% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ABBV: 21.20 )
ABBV' s 10-Year PFCF Range
Min: 8.64   Max: 23.55
Current: 21.2

8.64
23.55
POCF 18.52
ABBV's POCF is ranked higher than
86% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 38.72 vs. ABBV: 18.52 )
ABBV' s 10-Year POCF Range
Min: 8.19   Max: 20.87
Current: 18.52

8.19
20.87
EV-to-EBIT 20.02
ABBV's EV-to-EBIT is ranked higher than
86% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 35.35 vs. ABBV: 20.02 )
ABBV' s 10-Year EV-to-EBIT Range
Min: 10.3   Max: 22.2
Current: 20.02

10.3
22.2
PEG 6.40
ABBV's PEG is ranked higher than
86% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. ABBV: 6.40 )
ABBV' s 10-Year PEG Range
Min: 0   Max: 9989.5
Current: 6.4

0
9989.5
Current Ratio 2.65
ABBV's Current Ratio is ranked higher than
73% of the 881 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.41 vs. ABBV: 2.65 )
ABBV' s 10-Year Current Ratio Range
Min: 1.22   Max: 2.82
Current: 2.65

1.22
2.82
Quick Ratio 2.49
ABBV's Quick Ratio is ranked higher than
77% of the 881 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.83 vs. ABBV: 2.49 )
ABBV' s 10-Year Quick Ratio Range
Min: 1.06   Max: 2.65
Current: 2.49

1.06
2.65
Days Inventory 87.21
ABBV's Days Inventory is ranked higher than
86% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 149.40 vs. ABBV: 87.21 )
ABBV' s 10-Year Days Inventory Range
Min: 34.3   Max: 89.28
Current: 87.21

34.3
89.28
Days Sales Outstanding 74.32
ABBV's Days Sales Outstanding is ranked higher than
77% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 86.21 vs. ABBV: 74.32 )
ABBV' s 10-Year Days Sales Outstanding Range
Min: 79.87   Max: 93.3
Current: 74.32

79.87
93.3

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 2.80
ABBV's Dividend Yield is ranked higher than
87% of the 526 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.35 vs. ABBV: 2.80 )
ABBV' s 10-Year Dividend Yield Range
Min: 0.85   Max: 3.44
Current: 2.8

0.85
3.44
Dividend Payout 0.71
ABBV's Dividend Payout is ranked higher than
70% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.43 vs. ABBV: 0.71 )
ABBV' s 10-Year Dividend Payout Range
Min: 0.57   Max: 1.36
Current: 0.71

0.57
1.36
Yield on cost (5-Year) 2.80
ABBV's Yield on cost (5-Year) is ranked higher than
79% of the 535 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.46 vs. ABBV: 2.80 )
ABBV' s 10-Year Yield on cost (5-Year) Range
Min: 0.85   Max: 3.44
Current: 2.8

0.85
3.44

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.20
ABBV's Price/Median PS Value is ranked higher than
74% of the 959 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.29 vs. ABBV: 1.20 )
ABBV' s 10-Year Price/Median PS Value Range
Min: 0.7   Max: 1.14
Current: 1.2

0.7
1.14
Earnings Yield (Greenblatt) 5.00
ABBV's Earnings Yield (Greenblatt) is ranked higher than
85% of the 904 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.10 vs. ABBV: 5.00 )
ABBV' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4.5   Max: 9.7
Current: 5

4.5
9.7

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:ABBV.Switzerland, ABBV.France, 4AB.Germany, 0QCV.UK, ABBV.Mexico,
AbbVie Inc was incorporated in Delaware on April 10, 2012, and is a wholly owned subsidiary of Abbott. The company is a research-based biopharmaceutical company with portfolio of proprietary products including a broad line of adult and pediatric pharmaceuticals. The company discovers, develops, manufactures and sells proprietary pharmaceutical products. Its products are used to treat diseases including rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications. AbbVie also has a pipeline of new medicines, including more than 20 compounds or indications in Phase II or Phase III development across such important medical specialties as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. AbbVie operates in one business segment—pharmaceutical products. AbbVie competes with other research-based pharmaceuticals and biotechnology companies that discover, manufacture, market, and sell proprietary pharmaceutical products and biologics.
» More Articles for ABBV

Headlines

Articles On GuruFocus.com
Google Joins Biogen In The Fight Against Multiple Sclerosis Jan 29 2015 
What Could Be The Major Highlights In AbbVie’s Upcoming Earnings Call? Jan 29 2015 
Gilead Sciences Still has More Upside Jan 22 2015 
Has Gilead Sciences Been Able To Maintain Its Lead Run In The Face Of Competition? Jan 22 2015 
Shire Set To Acquire NPS Pharmaceuticals for $5.2 Billion Jan 15 2015 
AbbVie Inc.’s Forthcoming Future Looks Optimistic Jan 13 2015 
Gilead Strikes Deal with CVS, Hits Back AbbVie Jan 06 2015 
Is it Time to Sell Gilead Sciences? Dec 29 2014 
Express Scripts Knocks Gilead’s Hepatitis C Drug in Favor of AbbVie Dec 22 2014 
Is it Time to Sell Gilead Sciences? Dec 18 2014 


More From Other Websites
What to Expect When AbbVie (ABBV) Reports Fourth-Quarter Earnings Tomorrow Jan 29 2015
Abbott Labs' (ABT) Q4 Earnings Up, Guides Below Estimates - Analyst Blog Jan 29 2015
Why AbbVie (ABBV) Might Surprise This Earnings Season - Tale of the Tape Jan 29 2015
Roche Misses on Earnings in 2014, Beats on Revenues - Analyst Blog Jan 29 2015
Will Abbott Labs (ABT) Disappoint on Earnings This Quarter? - Analyst Blog Jan 28 2015
Is AbbVie (ABBV) Set to Beat 4Q Earnings on Humira Sales? - Analyst Blog Jan 28 2015
AmerisourceBergen's Revenue Growth May Slow Further Jan 28 2015
HALFTIME FINAL TRADES 1/28/15 Jan 28 2015
FMHR Final Trade: ABBV, PKI & CSX Jan 28 2015
Novartis (NVS) Up on Earnings and Revenue Beat in Q4 - Analyst Blog Jan 28 2015
Can St. Jude Medical (STJ) Keep Earnings Streak Alive? - Analyst Blog Jan 27 2015
Will Cardinal Health (CAH) Surprise Earnings This Season? - Analyst Blog Jan 27 2015
Will PerkinElmer's (PKI) Earnings Disappoint This Season? - Analyst Blog Jan 27 2015
Will AmerisourceBergen (ABC) Earnings Surprise in Q1? - Analyst Blog Jan 27 2015
Can Celgene (CELG) Beat Earnings on Strong Product Sales? - Analyst Blog Jan 27 2015
Varian Medical (VAR): Will Earnings Disappoint in Q1? - Analyst Blog Jan 27 2015
Will Baxter International (BAX) Disappoint Earnings in Q4? - Analyst Blog Jan 27 2015
Will Alexion's (ALXN) Soliris Drive Q4 Earnings Beat? - Analyst Blog Jan 27 2015
AbbVie Hepatitis C Drug Will Be Focus of Profit Report --- Earnings Preview Jan 27 2015
Will Biogen (BIIB) Surpass Q4 Earnings Expectations? - Analyst Blog Jan 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK